A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Completed · Phase 1/Phase 2

Conditions studied: Relapsed or Refractory Multiple Myeloma

In brief

This is a Phase I-Ib/II, open-label, multicenter study of AUY922 administered intravenously in patients with multiple myeloma to determine the maximum tolerated dose. The Phase II part will investigate the efficacy of AUY922 in patients with multiple myeloma. Additionally, the study includes a Phase Ib combination part of AUY922 administered in combination with bortezomib, to determine the maximum tolerated dose of the combination drugs in patients with multiple myeloma.

Key facts

Study ID

NCT00708292

Run by

Novartis Pharmaceuticals

People needed

29

Starts

2008-07-01

Expected to finish

2011-01-01

Last updated by the study team

2020-12-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have a diagnosis of active multiple myeloma.
• Phase I and Phase II part: Patients must have received at least 2 but not more than 4 prior line of therapy and their disease has progressed during or after last therapy.
• Phase Ib part: Patients must have received no more than 2 prior lines of therapy (excluding dexamethasone as single agent).
• ECOG Performance Status of ≤ 2.
• Patients must have acceptable neutrophil and platelet counts as well as adequate kidney and liver function.
• Patients must have magnesium levels above lower limit of normal or correctable with supplements.
• Patients must be willing and able to undergo bone marrow biopsy/aspirate.
• Able to sign informed consent.

You may not qualify if…

• Prior treatment with any HSP90 or HDAC inhibitor for the treatment of multiple myeloma.
• Patients with unresolved diarrhea ≥ CTCAE grade 2.
• Patients with acute or chronic liver disease.
• Patients using medications that have a relative risk of prolonging the QT interval.
• Clinically significant cardiac diseases.
• Patients with known disorders due to a deficiency in bilirubin glucuronidation (e.g. Gilbert's syndrome).
• Pregnant or lactating women.
• Fertile women of childbearing potential (WCBP) not using adequate contraception.
• Male patients whose partners are WCBP, not using adequate contraception.
• Patients who unwilling or unable to comply with the protocol.
• Phase Ib part: Peripheral neuropathy ≥ CTCAE grade 1.
• Phase Ib part: Prior treatment with bortezomib.
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Mayo Clinic - Arizona Cancer Clinical Research Unit — Scottsdale, Arizona, United States
• Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(3) — San Antonio, Texas, United States
• Novartis Investigative Site — Melbourne, Australia
• Novartis Investigative Site — Frankfurt, Germany
• Novartis Investigative Site — München, Germany
• Novartis Investigative Site — Würzburg, Germany
• Novartis Investigative Site — Singapore, Singapore
• Novartis Investigative Site — Barcelona, Catalonia, Spain
• Novartis Investigative Site — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.